CD44 and cancer: A series of ligand‐receptor pairs are abundant in both adjacent and RB1‐CN‐wildtype or RB1‐CN‐wildtype alone, with the exception of the SPP1–CD44 interaction (Figure S4F), which is involved in tissue damage in the immune response to cancer and poor prognosis in cancer [30, 31].